Skip to main content
NCBI home page
British Journal of Clinical Pharmacology logoLink to British Journal of Clinical Pharmacology
. 1975 Dec;2(6):515–519. doi: 10.1111/j.1365-2125.1975.tb00569.x

Procainamide absorption studies to test the feasibility of using a sustained-release preparation.

T R Shaw, C R Kumana, C M Kaye, C Padgham, T Kaspi, J Hamer
PMCID: PMC1402637  PMID: 1234015

Abstract

Using in vitro techniques it was confirmed that whilst the release of procainamide from the conventional formulation (Pronestyl) was rapid, that from the sustained-release preparation (Cardiorytmin Retard) occurred over a prolonged period. 2 The peak plasma procainamide concentrations after single doses of Cardiorytmin Retard were relatively lower and occurred later than those after single doses of Pronestyl. Furthermore, after reaching a peak, the fall in plasma procainamide concentration was less rapid after the sustained-release preparation. Early urinary recovery of procainamide in patients and in healthy volunteers was greater after Pronestyl than after Cardiorytmin Retard, though overall recovery in urine was similar. These findings indicate that the absorption of the sustained-release preparation is slower, though the overall bioavailabilities of the two preparations are almost the same. 3 These results confirm the feasibility of using a sustained-release procainamide preparation, such as Cardiorytmin Retard, since it would be possible to administer the same amount of drug in fewer daily doses without plasma concentrations becoming ineffective towards the end of each dosing interval.

Full text

PDF
515

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Bigger J. T., Jr, Heissenbuttel R. H. The use of procaine amide and lidocaine in the treatment of cardiac arrhythmias. Prog Cardiovasc Dis. 1969 May;11(6):515–534. doi: 10.1016/0033-0620(69)90004-8. [DOI] [PubMed] [Google Scholar]
  2. Denborough M. A., Lovell R. R., Nestel P. J., Goble A. J. Arrhythmias and late sudden death after myocardial infarction. Lancet. 1968 Feb 24;1(7539):386–388. doi: 10.1016/s0140-6736(68)91354-8. [DOI] [PubMed] [Google Scholar]
  3. Drayer D. E., Reidenberg M. M., Sevy R. W. N-acetylprocainamide: an active metabolite of procainamide. Proc Soc Exp Biol Med. 1974 Jun;146(2):358–363. doi: 10.3181/00379727-146-38104. [DOI] [PubMed] [Google Scholar]
  4. Dreyfuss J., Bigger J. T., Jr, Cohen A. I., Schreiber E. C. Metabolism of procainamide in rhesus monkey and man. Clin Pharmacol Ther. 1972 May-Jun;13(3):366–371. doi: 10.1002/cpt1972133366. [DOI] [PubMed] [Google Scholar]
  5. Elson J., Strong J. M., Lee W. K., Atkinson A. J., Jr Antiarrhythmic potency of N-acetylprocainamide. Clin Pharmacol Ther. 1975 Feb;17(2):134–140. doi: 10.1002/cpt1975172134. [DOI] [PubMed] [Google Scholar]
  6. Fremstad D., Dahl S., Jacobsen S., Lunde P. K., Nådland K. J., Marthinsen A. A., Waaler T., Landmark K. H. A new sustained-release tablet formulation of procainamide. Eur J Clin Pharmacol. 1973 Dec;6(4):251–255. doi: 10.1007/BF00644741. [DOI] [PubMed] [Google Scholar]
  7. Giardina E. G., Heissenbuttel R. H., Bigger J. T., Jr Intermittent intravenous procaine amide to treat ventricular arrhythmias. Correlation of plasma concentration with effect on arrhythmia, electrocardiogram, and blood pressure. Ann Intern Med. 1973 Feb;78(2):183–193. doi: 10.7326/0003-4819-78-2-183. [DOI] [PubMed] [Google Scholar]
  8. Karlsson E., Aberg G., Collste P., Molin L., Norlander B., Sjöqvist F. Acetylation of procaine amide in man. A preliminary communication. Eur J Clin Pharmacol. 1975;8(1):79–81. doi: 10.1007/BF00616419. [DOI] [PubMed] [Google Scholar]
  9. Karlsson E. Plasma levels of procaine amide after administration of conventional and sustained-release tablets. Eur J Clin Pharmacol. 1973 Dec;6(4):245–250. doi: 10.1007/BF00644740. [DOI] [PubMed] [Google Scholar]
  10. Koch-Weser J., Klein S. W., Foo-Canto L. L., Kastor J. A., DeSanctis R. W. Antiarrhythmic prophylaxis with procainamide in acute myocardial infarction. N Engl J Med. 1969 Dec 4;281(23):1253–1260. doi: 10.1056/NEJM196912042812301. [DOI] [PubMed] [Google Scholar]
  11. Koch-Weser J., Klein S. W. Procainamide dosage schedules, plasma concentrations, and clinical effects. JAMA. 1971 Mar 1;215(9):1454–1460. [PubMed] [Google Scholar]
  12. Lawrie D. M. Long-term survival after ventricular fibrillation complicating acute myocardial infarction. Lancet. 1969 Nov 22;2(7630):1085–1087. doi: 10.1016/s0140-6736(69)90697-7. [DOI] [PubMed] [Google Scholar]
  13. MARK L. C., KAYDEN H. J., STEELE J. M., COOPER J. R., BERLIN I., ROVENSTINE E. A., BRODIE B. B. The physiological disposition and cardiac effects of procaine amide. J Pharmacol Exp Ther. 1951 May;102(1):5–15. [PubMed] [Google Scholar]
  14. Meyer W., Kaye C. M., Turner P. A study of the influence of pH on the buccal absorption and renal excretion of procainamide. Eur J Clin Pharmacol. 1974 Jul 26;7(4):287–289. doi: 10.1007/BF00560346. [DOI] [PubMed] [Google Scholar]
  15. Norris R. M., Bensley K. E., Caughey D. E., Scott P. J. Hospital mortality in acute myocardial infarction. Br Med J. 1968 Jul 20;3(5611):143–146. doi: 10.1136/bmj.3.5611.143. [DOI] [PMC free article] [PubMed] [Google Scholar]
  16. Ruosteenoja R., Torsti P., Sothmann A. Experiences on a sustained-release procainamide preparation. Curr Ther Res Clin Exp. 1973 Oct;15(10):707–712. [PubMed] [Google Scholar]
  17. Shaw T. R., Kumana C. R., Royds R. B., Padgham C. M., Hamer J. Use of plasma levels in evaluation of procainamide dosage. Br Heart J. 1974 Mar;36(3):265–270. doi: 10.1136/hrt.36.3.265. [DOI] [PMC free article] [PubMed] [Google Scholar]

Articles from British Journal of Clinical Pharmacology are provided here courtesy of British Pharmacological Society

RESOURCES